Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SQXAL
ADC Name
ARX-517
Synonyms
ARX 517; ARX-517; ARX517
   Click to Show/Hide
Organization
Ambrx, Inc.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Prostate cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
2
Structure
Antibody Name
Undisclosed; a humanized anti-PSMA antibody, https://aacrjournals.org/mct/article/23/12/1842/750247
  Antibody Info 
Antigen Name
Glutamate carboxypeptidase 2 (FOLH1)
  Antigen Info 
Payload Name
Monomethyl auristatin F
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Oxime-PEG3
  Linker Info 
Conjugate Type
Non-natural Amino Acids
Combination Type
amberstatin
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT04662580
Phase 1/2
A phase 1/2, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of ARX517, with randomized comparison to investigator's choice of treatment, in subjects with metastatic castration-resistant prostate cancer who are resistant or refractory to prior standard therapies.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT04662580  Clinical Status Phase 1/2
Clinical Description A phase 1/2, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of ARX517, with randomized comparison to investigator's choice of treatment, in subjects with metastatic castration-resistant prostate cancer who are resistant or refractory to prior standard therapies.
References
Ref 1 A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517, With Randomized Comparison to Investigator's Choice of Treatment, in Subjects With Metastatic Castration-resistant Prostate Cancer Who Are Resistant or Refractory to Prior Standard Therapies, NCT04662580